Researchers find that surgical decision making is often driven by factors beyond extent of disease. Among breast cancer patients on adjuvant trastuzumab, lisinopril and carvedilol reduced cardiotoxicity, but only for those in the anthracycline cohort. The immune marker PD1 may be prognostic for survival in patients with TNBC who achieve a pathologic complete response after neoadjuvant therapy.
Refer back to this page often to read the latest news from SABCS, see perspectives and interviews with leading researchers and clinicians, and review archives of past meetings. Tell us what you think about Healio. Login Register My Saved.
Final titles and speakers will follow. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.
By Caroline Helwick February 10, Advertisement. The following are his choices for and comments about studies that may be practice-changing. At 3 years, invasive disease—free survival was The striking homogeneity of benefit across all the major subgroups was considered one of the remarkable findings of the study.
The estimated count of participants is calculated by multiplying the normalized participant interest generated on platform with a regional multiplier. Organizers can update the count here. Civil Engineer at Winteck Nigeria Limited.
We invite abstracts of proffered papers on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease. Submission deadline is July 8, The deadline for booking a reservation is November 22,
From a one-day regional conference, the Symposium has grown to a five-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries. The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer. This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.
To make your hotel reservation, please click here. Click here for Registration form. Refunds for hotel discount will not be issued once payment for registration has been received. Press: Visit the Media page on our website for registration information.
This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers. The scientific program consists of formal lectures by experts in clinical and basic research, selected slide and poster presentations, forums and case discussions. The official language of the symposium is English.
If you have any questions, please contact us and let us know. Refunds will not be granted after November 22, nor will they be given for no-shows. Please email cancellations to sabcs uthscsa. Late Submission Abstracts A late submission abstract refers only to paradigm shifting basic science discovery, or translational or clinical research of relevance to patients.